Study of IPX-203 for Parkinson's disease (BOOST-PD)
Part of Brain & nervous system clinical trials.
This study tests a new formulation of carbidopa-levodopa (IPX-203) to see how well it works for people with Parkinson's disease. It uses a wearable device to measure movement and aims to improve “off” time, when symptoms return between doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older.
- You have been diagnosed with idiopathic Parkinson's disease and your symptoms respond to levodopa.
- You currently take carbidopa-levodopa (such as Sinemet or Rytary) and have been on a stable dose for at least 4 weeks.
- You have at least 2 hours of “off” time each day.
- You are able to wear a small device (like a watch) that tracks your movements.
- You do not have severe dyskinesia (uncontrolled twisting or jerking movements) or certain other serious complications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well CREXONT, an extended-release form of carbidopa-levodopa, controls symptoms in people with Parkinson's who experience predictable 'off' periods when their regular medication wears off. The goal is to see if it can reduce the daily hours of poor mobility.
This study is looking at how a new continuous 24-hour injection treatment (foslevodopa/foscarbidopa) affects quality of life in people with advanced Parkinson's disease. It is a real-world study, meaning you just take the medication as your doctor prescribes, and researchers observe the results.
This trial tests an investigational drug called IPS101A in people with advanced Parkinson's disease. It aims to see if the drug is safe and how well it works when standard treatments are no longer enough.
This trial tests an experimental drug called AP-472, taken alongside your regular Parkinson's medications, to see if it can reduce the amount of "OFF" time you experience each day when symptoms return between doses of levodopa.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This study tests a new single-dose treatment for Parkinson's disease to see if it can help reduce 'off' time—when medication wears off and symptoms return. It is for people who experience motor fluctuations and are already on a stable medication routine.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.